About Syneron Medical (NASDAQ:ELOS)
Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company's aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company's products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ELOS
CUSIPN/A
Phone+972-7-32442200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.68%
Quick Ratio1.84%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1.09%
Return on Equity-1.74%
Return on Assets-1.30%
Miscellaneous
Employees817
Outstanding Shares35,230,000
Syneron Medical (NASDAQ:ELOS) Frequently Asked Questions
What is Syneron Medical's stock symbol?
Syneron Medical trades on the NASDAQ under the ticker symbol "ELOS."
How were Syneron Medical's earnings last quarter?
Syneron Medical Ltd. (NASDAQ:ELOS) released its quarterly earnings results on Thursday, August, 4th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.03. The medical equipment provider had revenue of $75 million for the quarter, compared to analysts' expectations of $75.72 million. Syneron Medical had a negative net margin of 1.09% and a negative return on equity of 1.74%. The firm's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS. View Syneron Medical's Earnings History.
What price target have analysts set for ELOS?
1 Wall Street analysts have issued 1-year price objectives for Syneron Medical's stock. Their predictions range from $11.00 to $11.00. On average, they expect Syneron Medical's stock price to reach $11.00 in the next year. View Analyst Ratings for Syneron Medical.
Who are some of Syneron Medical's key competitors?
Some companies that are related to Syneron Medical include Star Bulk Carriers (SBLK), Horizon Bancorp (IN) (HBNC), Raptor Pharmaceutical (RPTP), Monarch Casino & Resort (MCRI), EZchip Semiconductor (EZCH), OptiNose (OPTN), Partner Communications (PTNR), IXYS (IXYS), TPI Composites (TPIC), Qiwi (QIWI), Nova Measuring Instruments (NVMI), Midland States Bancorp (MSBI), Aegion (AEGN), Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA) and Cardiovascular Systems (CSII).
Who are Syneron Medical's key executives?
Syneron Medical's management team includes the folowing people:
- Shimon Eckhouse Ph.D., Chairman of the Board
- Amit Meridor, Chief Executive Officer
- , Bio & Compensation -
- Hugo Goldman, Chief Financial Officer
- , Bio & Compensation -
- Erik Dowell, Vice President-North America
- William Griffing, Chief Executive Officer - Syneron Candela North America
- Shlomo Alkalay, Chief Operating Officer
- Lisa A. Soderquist, Chief Human Resource Officer
- , Bio & Compensation -
- Robert Ruck, Executive Vice President, Asia Pacific
- Robert Fielitz, Vice President and Managing Director of Europe, Middle East and Africa
- Sarit Soccary Ben-Yochanan, Vice President - Business Development & Strategy
Has Syneron Medical been receiving favorable news coverage?
News headlines about ELOS stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syneron Medical earned a news sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 45.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Syneron Medical?
Shares of ELOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneron Medical's stock price today?
One share of ELOS stock can currently be purchased for approximately $11.00.
How big of a company is Syneron Medical?
Syneron Medical has a market capitalization of $387.56 million. Syneron Medical employs 817 workers across the globe.
How can I contact Syneron Medical?
Syneron Medical's mailing address is Tavor Building 4 P.O. Box 550, YOKNEAM, 2069200, Israel. The medical equipment provider can be reached via phone at +972-7-32442200.
MarketBeat Community Rating for Syneron Medical (ELOS)
MarketBeat's community ratings are surveys of what our community members think about Syneron Medical and other stocks. Vote "Outperform" if you believe ELOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Syneron Medical (NASDAQ:ELOS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Syneron Medical in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible downside of 0.00%. The high price target for ELOS is $11.00 and the low price target for ELOS is $11.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.00 | $11.00 | $11.00 | $11.00 |
| Price Target Upside: | 0.00% downside | 1.38% upside | 1.38% upside | 1.38% upside |
Syneron Medical (NASDAQ:ELOS) Consensus Price Target History
Syneron Medical (NASDAQ:ELOS) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/12/2017 | Maxim Group | Downgrade | Buy -> Hold | $12.00 -> $11.00 | Medium |  |
| 10/24/2016 | Brean Capital | Reiterated Rating | Buy | | N/A | |
| 8/5/2016 | Leerink Swann | Downgrade | Outperform -> Market Perform | $9.40 -> $7.80 | N/A | |
(Data available from 4/22/2016 forward)
Syneron Medical (NASDAQ:ELOS) Earnings History and Estimates Chart
Syneron Medical (NASDAQ ELOS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/17/2017 | Q1 2017 | | ($0.14) | $69.60 million | $66.88 million | View | N/A | |
| 2/15/2017 | Q416 | $0.03 | ($0.03) | $82.02 million | $82.90 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.02) | $0.02 | $68.08 million | $71.50 million | View | Listen | |
| 8/4/2016 | Q216 | $0.06 | $0.09 | $75.72 million | $75.00 million | View | Listen | |
| 5/19/2016 | Q116 | $0.01 | $0.04 | $64.38 million | $68.70 million | View | Listen | |
| 2/22/2016 | Q415 | $0.07 | $0.07 | $75.56 million | $78.90 million | View | Listen | |
| 11/11/2015 | Q315 | $0.03 | $0.03 | $66.60 million | $62.10 million | View | Listen | |
| 8/4/2015 | Q215 | $0.06 | $0.04 | $70.93 million | $73.50 million | View | N/A | |
| 5/13/2015 | Q115 | $0.01 | $0.02 | $62.08 million | $63.40 million | View | Listen | |
| 2/18/2015 | Q414 | $0.06 | $0.09 | $71.42 million | $74.10 million | View | N/A | |
| 11/12/2014 | Q314 | $0.03 | $0.03 | $58.32 million | $60.30 million | View | N/A | |
| 8/6/2014 | Q214 | $0.07 | $0.07 | $63.52 million | $64.60 million | View | Listen | |
| 5/14/2014 | Q114 | $0.04 | $0.04 | $55.50 million | $56.80 million | View | N/A | |
| 2/20/2014 | Q413 | $0.08 | $0.11 | $65.70 million | $64.30 million | View | Listen | |
| 11/13/2013 | Q313 | $0.01 | $0.04 | $62.06 million | $62.70 million | View | Listen | |
| 8/14/2013 | Q2 2013 | $0.09 | $0.02 | $70.93 million | $68.80 million | View | N/A | |
| 5/22/2013 | Q1 2013 | $0.02 | $0.02 | $61.19 million | $61.20 million | View | N/A | |
| 2/12/2013 | Q4 2012 | $0.09 | $0.11 | $70.60 million | $72.80 million | View | N/A | |
| 11/7/2012 | Q312 | $0.04 | $0.03 | $65.51 million | $60.13 million | View | N/A | |
| 8/15/2012 | | $0.04 | $0.05 | | | View | N/A | |
| 5/9/2012 | Q1 2012 | ($0.12) | ($0.01) | | | View | N/A | |
| 2/9/2012 | | $0.04 | $0.03 | | | View | N/A | |
| 11/10/2011 | | ($0.09) | ($0.03) | | | View | N/A | |
| 8/11/2011 | | ($0.02) | ($0.01) | | | View | N/A | |
| 5/19/2011 | | ($0.04) | $0.01 | | | View | N/A | |
| 2/16/2011 | | ($0.04) | $0.24 | | | View | N/A | |
| 11/11/2010 | Q3 2010 | ($0.16) | ($0.07) | | | View | N/A | |
| 8/12/2010 | Q2 2010 | ($0.12) | ($0.13) | | | View | N/A | |
| 5/13/2010 | Q1 2010 | ($0.10) | ($0.17) | | | View | N/A | |
| 2/11/2010 | Q4 2009 | ($0.11) | ($0.16) | | | View | N/A | |
| 11/9/2009 | Q3 2009 | ($0.15) | ($0.20) | | | View | N/A | |
| 8/13/2009 | Q2 2009 | ($0.22) | ($0.20) | | | View | N/A | |
| 5/14/2009 | Q1 2009 | ($0.20) | ($0.30) | | | View | N/A | |
| 2/12/2009 | Q4 2008 | $0.08 | ($0.58) | | | View | N/A | |
| 11/11/2008 | Q3 2008 | $0.12 | $0.08 | | | View | N/A | |
| 8/14/2008 | Q2 2008 | $0.34 | $0.32 | | | View | N/A | |
| 5/14/2008 | Q1 2008 | $0.30 | $0.30 | | | View | N/A | |
| 2/12/2008 | Q4 2007 | $0.34 | $0.37 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Syneron Medical (NASDAQ:ELOS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Syneron Medical (NASDAQ ELOS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 69.17%
Syneron Medical (NASDAQ ELOS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Syneron Medical (NASDAQ ELOS) News Headlines
| Source: |
|
Syneron Medical (NASDAQ:ELOS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Syneron Medical (NASDAQ:ELOS) Income Statement, Balance Sheet and Cash Flow Statement
Syneron Medical (NASDAQ ELOS) Stock Chart for Sunday, April, 22, 2018
Loading chart…
